Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3441-3443

  Albur, Mahableshwar ^a   Noel, Alan ^a   Bowker, Karen ^a   MacGowan, Alasdair ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; TIGECYCLINE;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONCENTRATION RESPONSE; DRUG ANTAGONISM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLISTIN; DRUG ANTAGONISM; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84861117552     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05682-11     Document Type: Article

References (14)

1. Cai Y, Wang R, Liang B, Bai N, Liu Y. 2011. Effectiveness and safety of tigecycline for the treatment of infectious disease: a systematic review and meta-analysis. Antimicrob. Agents Chemother. 55:1162-1172.
2. Dollery C. 1999. Therapeutic drugs, 2nd ed, C326. Churchill Livingstone, Philadelphia, PA.
3. Dudhani RV, et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
4. Grayson LM, et al. 2010. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs, 6th ed, p 885, Table 69.2. Hodder Arnold, London, United Kingdom.
5. Kumarasamy KK, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602.
6. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. 2001. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:781-785. (Pubitemid 32182025)
7. Li J, et al. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. (Pubitemid 38008420)
8. MacGowan A, Bowker K. 2002. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents 19:291-298. (Pubitemid 34308977)
9. Markou N, et al. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30:143-151. (Pubitemid 351834728)
10. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. 2010. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54:4914-4916.
11. Poirel L, Revathi G, Bernabeu S, Nordmann P. 2011. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother. 55:934-936.
12. Rynn C, Wootton M, Bowker KE, Alan Holt H, Reeves DS. 1999. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin. Microbiol. Infect. 5:32-36. (Pubitemid 29055906)
13. Solé M, et al. 2011. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob. Agents Chemother. 55: 4402-4404.
14. Yahav D, Lador A, Paul M, Leibovici L. 2011. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66:1963-1971.